This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
When cinchophen, or phenylcinchoninic acid, was introduced into therapeutics, about 1908 (reinforced by the trade name "Atophan"—the tophi remover), its striking effect on the elimination of uric acid captured the clinical imagination, which was at that time perhaps somewhat overconscious of uric acid. The product attained immediate popularity. The uric acid complex receded, and it was soon seen that atophan belied its name, for the tophi proved unreasonable and refused to be removed. The drug was found, however, to be an effective analgesic, much like the salicylates, with which it has many points of similarity. Since the taste is different, the popularity of cinchophen continued to increase, so much so that it achieved a place in the United States Pharmacopeia. Various esters and derivatives were advertised extensively for the benefit of those who do not like the flavor of cinchophen and incidentally for the benefit of the manufacturers, who could
ATROPHY OF THE LIVER DUE TO CINCHOPHEN PREPARATIONS. JAMA. 1930;95(5):345–346. doi:10.1001/jama.1930.02720050033013
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.